Literature DB >> 18667637

Characterization of new formalin-detoxified botulinum neurotoxin toxoids.

James E Keller1.   

Abstract

Antigenicities of several formalin-detoxified botulinum neurotoxin preparations were measured by inhibition and sandwich enzyme-linked immunosorbent assay (ELISA), and immunogenicity was studied in mice. The toxoids were derived primarily from the serotype A 150-kDa neurotoxin protein, while one toxoid was derived from the naturally occurring 900-kDa toxin-hemagglutinin complex. Antigenicity was severely compromised in two commercially available toxoids. A variety of new toxoids were synthesized in-house by optimizing formaldehyde reaction conditions. Three of the resulting toxoids were found to be antigenically identical to the native toxin, as measured by inhibition ELISA, in spite of showing a reduction of toxicity by more than 100,000-fold. Sandwich ELISAs indicated that the in-house toxoids were two- to threefold less antigenic than the neurotoxin compared to commercial toxoids, which were about 100-fold less antigenic. Mice were immunized twice, on day 0 and day 14. By day 28, relatively high toxin-specific immunoglobulin G (IgG) titers were detected in animals that had received any of the in-house toxoids, with greater than 99% being IgG1 and the remainder being IgG2. These immunized mice remained asymptomatic after being challenged with 50 to 1,000,000 50% lethal dose (LD(50)) units of the 900-kDa neurotoxin. In contrast, animals immunized with several different batches of commercially available toxoids did not develop measurable toxin-specific antibody titers. However, these mice survived neurotoxin challenges with 2 LD(50) units but died when challenged with 6 LD(50) units. Neutralizing titers measured from pools of sera generated with the in-house toxoid preparations ranged from 2.5 to 5 U/ml. In terms of predicting immunogenicity, inhibition ELISAs comparing each formalin toxoid to the parent toxin provided good insight for screening the new toxoids as well as for estimating their relative in vivo potencies. Inhibition ELISA data indicate that those toxoids that most closely resemble the native toxin are highly immunogenic and protective. The superior quality of these new toxoids makes them useful tools for continued use in ELISA development and for antitoxin production.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667637      PMCID: PMC2546675          DOI: 10.1128/CVI.00117-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  35 in total

1.  Studies on immunity to toxins of Clostridium botulinum. V. Detoxification of purified type A and type B toxins, and the antigenicity of univalent and bivalent aluminium phosphate adsorbed toxoids.

Authors:  G G WRIGHT; J T DUFF; M A FIOCK; H B DEVLIN; R L SODERSTROM
Journal:  J Immunol       Date:  1960-04       Impact factor: 5.422

2.  Reaction of formaldehyde with proteins; cross-linking of amino groups with phenol, imidazole, or indole groups.

Authors:  H FRAENKEL-CONRAT; H S OLCOTT
Journal:  J Biol Chem       Date:  1948-07       Impact factor: 5.157

3.  Factors affecting the botulinal hemagglutination reaction, and the relationship between hemagglutinating activity and toxicity of toxin preparations.

Authors:  J P LOWENTHAL; C LAMANNA
Journal:  Am J Hyg       Date:  1951-11

4.  The lack of identity between hemagglutinin and the toxin of type A botulinal organism.

Authors:  C LAMANNA; J P LOWENTHAL
Journal:  J Bacteriol       Date:  1951-06       Impact factor: 3.490

5.  An improved method for development of toxoid vaccines and antitoxins.

Authors:  Russell G A Jones; Yvonne Liu; Peter Rigsby; Dorothea Sesardic
Journal:  J Immunol Methods       Date:  2008-06-09       Impact factor: 2.303

6.  Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid.

Authors:  Phillip R Pittman; Dallas Hack; Joseph Mangiafico; Paul Gibbs; Kelly T McKee; Arthur M Friedlander; Maria H Sjogren
Journal:  Vaccine       Date:  2002-05-15       Impact factor: 3.641

7.  Oral toxicities of Clostridium botulinum toxins in response to molecular size.

Authors:  I Ohishi; S Sugii; G Sakaguchi
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

8.  Subunit vaccine against the seven serotypes of botulism.

Authors:  Michael R Baldwin; William H Tepp; Amanda Przedpelski; Christina L Pier; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

9.  Identification of formaldehyde-induced modifications in proteins: reactions with model peptides.

Authors:  Bernard Metz; Gideon F A Kersten; Peter Hoogerhout; Humphrey F Brugghe; Hans A M Timmermans; Ad de Jong; Hugo Meiring; Jan ten Hove; Wim E Hennink; Daan J A Crommelin; Wim Jiskoot
Journal:  J Biol Chem       Date:  2003-11-24       Impact factor: 5.157

10.  Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate.

Authors:  M P Byrne; T J Smith; V A Montgomery; L A Smith
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

View more
  8 in total

1.  Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.

Authors:  Waleed Mustafa; Fetweh H Al-Saleem; Zidoon Nasser; Rebecca M Olson; Jeffrey A Mattis; Lance L Simpson; Matthias J Schnell
Journal:  Vaccine       Date:  2011-05-05       Impact factor: 3.641

2.  New equine antitoxins to botulinum neurotoxins serotypes A and B.

Authors:  D Li; P Mattoo; J E Keller
Journal:  Biologicals       Date:  2012-05-05       Impact factor: 1.856

3.  A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication.

Authors:  Chi Ho Yu; Dong Hyun Song; Jun Young Choi; Hae Eun Joe; Woo Hyeon Jeong; Gyeung Haeng Hur; Young Kee Shin; Seong Tae Jeong
Journal:  Hum Vaccin Immunother       Date:  2017-12-19       Impact factor: 3.452

Review 4.  Vaccine Production to Protect Animals Against Pathogenic Clostridia.

Authors:  Nicolas E Zaragoza; Camila A Orellana; Glenn A Moonen; George Moutafis; Esteban Marcellin
Journal:  Toxins (Basel)       Date:  2019-09-11       Impact factor: 4.546

5.  SERS detection of Clostridium botulinum neurotoxin serotypes A and B in buffer and serum: Towards the development of a biodefense test platform.

Authors:  China Y Lim; Jennifer H Granger; Marc D Porter
Journal:  Anal Chim Acta X       Date:  2018-12-21

6.  Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents.

Authors:  Jerry O Conway; Laura J Sherwood; M Thelma Collazo; John A Garza; Andrew Hayhurst
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

Review 7.  Antibodies and Vaccines against Botulinum Toxins: Available Measures and Novel Approaches.

Authors:  Christine Rasetti-Escargueil; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2019-09-12       Impact factor: 4.546

8.  A Novel High-Potency Tetanus Vaccine.

Authors:  Amanda Przedpelski; William H Tepp; Sabine Pellett; Eric A Johnson; Joseph T Barbieri
Journal:  mBio       Date:  2020-08-11       Impact factor: 7.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.